OX124 - Opioid overdose rescue drug

Short facts  
API Naloxone
Technology Nasal
Indication Opioid overdose
Development phase Finalized phase 1, the pivotal trial OX124-002 commenced on July 15 2021
Expected filing with FDA In the second half of 2022
In-house or partnership In-house

Unmet need
Available rescue medications have been developed for heroin overdoses, but most patients are dying from synthetic opioids like fentanyl today.

Our aim
Based on Orexo´s novel intranasal formulation technology, the aim is to develop a rescue medication that is faster and longer-acting, and thus effective in reversing overdoses caused by synthetic opioids.

Results from the exploratory pharmacokinetic study (PK-study) in healthy volunteers showed significantly better PK-profile, such as faster and longer-acting, when compared to the market leading product. Novel, proprietary drug delivery technology with patent protection until 2039.